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The H+-coupled amino acid transporter PAT2 (SLC36A2) transports the amino acids proline, glycine, alanine
and hydroxyproline. A physiological role played by PAT2 in amino acid reabsorption in the renal proximal
tubule is demonstrated by mutations in SLC36A2 that lead to an iminoglycinuric phenotype (imino acid and
glycine uria) in humans. A number of proline, GABA and tryptophan derivatives were examined to determine
if they function either as transported substrates or non-transported inhibitors of PAT2. The compounds were
investigated following heterologous expression of rat PAT2 in Xenopus laevis oocytes. PAT2 function was
characterised by: radiotracer uptake and competition (cis-inhibition) studies; radiotracer efﬂux and trans-
stimulation; and measurement of substrate-induced positive inward current by two-electrode voltage-
clamp. In general, the proline derivatives appeared to be transported substrates and the relative ability to
induce current ﬂow was closely related to the inhibitory effects on PAT2-mediated L-[3H]proline uptake. In
contrast, certain heterocyclic GABA derivatives (e.g. L-pipecolic acid) were translocated only slowly. Finally,
the tryptophan derivatives inhibited PAT2 function but did not undergo transport. L-Proline uptake
was inhibited by 5-hydroxy-L-tryptophan (IC50 1.6±0.4 mM), α-methyl-D,L-tryptophan (3.5±1.5 mM), L-
tryptophan, 1-methyl-L-tryptophan and indole-3-propionic acid. Although neither 5-hydroxy-L-tryptophan
nor α-methyl-D,L-tryptophan were able to elicit inward current in PAT2-expressing oocytes both reduced the
current evoked by L-proline. 5-Hydroxy-L-tryptophan and α-methyl-D,L-tryptophan were unable to trans-
stimulate L-proline efﬂux from PAT2-expressing oocytes, conﬁrming that the two compounds act as non-
transported blockers of PAT2. These two tryptophan derivatives should prove valuable experimental tools in
future investigations of the physiological roles of PAT2.
© 2010 Elsevier B.V.
1. Introduction
The SLC36 (solute carrier 36) family of transporter-related genes
consists of four members (SLC36A1–4) in all mammalian genomes
investigated thus far [1–3]. The SLC36 transporters, along with the
SLC32 and SLC38 families (categorised using the nomenclature of the
Human Genome Organisation [4]), form the β-group cluster of amino
acid transporters [5] and are members of the Amino Acid/Auxin
Permease (AAAP) family. The AAAP family is contained within the
amino acid/polyamine/organocation (APC) transporter superfamily,
as classiﬁed using the nomenclature of the Transport Classiﬁcation
Database [6].
The SLC36A1 gene encodes a H+-coupled amino acid transporter
named variously as LYAAT1 or PAT1 [7]. cDNAs for PAT1 have been
isolated from rat [8], mouse [9], human [10] and rabbit [11]. When
expressed in a heterologous system, PAT1 produces an amino acid
transporter that has the functional characteristics of a transport system
(named system PAT for Proton-coupled Amino acid Transporter)
previously identiﬁed at the apical membrane of monolayers of the
human intestinal epithelial cell line Caco-2 [12,13]. PAT1 has been
identiﬁed as the molecular correlate of the imino acid carrier [14], a
transport system identiﬁed functionally in rat small intestine as longago
as the 1960s [15–17]. The potential importance of PAT1 in amino acid
absorption in the mammalian small intestine is demonstrated by
immunolocalisation of PAT1 protein to the luminal surfaceof Caco-2 cell
monolayers, and both human and rat small intestine [7,14]. The
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transports awide variety of L- and D-amino and imino acids inα-,β- and
γ-orientations, and a large number of heterocyclic compounds and
orally-delivered drugs related to proline and GABA (for examples see
[7,9,13,14,18–23]). Recently PAT1 has been shown to transport the
conditionally-essential amino acid taurine [24] and the photosensitising
anti-cancer agent δ-aminolevulinic acid [25].
In contrast to PAT1, much less is known about the other members
of the SLC36 family. SLC36A3/PAT3 and SLC36A4/PAT4 remain orphan
transporters with no known function. Based upon homology to PAT1
(for example, human PAT1 and PAT2 (SLC36A2) share 72% identity in
amino acid sequence), PAT2 was isolated from mouse [9], rat [1] and
human [2]. Like PAT1, PAT2 functions as an H+-coupled amino acid
transport system when expressed in Xenopus laevis oocytes or human
RPE cells. PAT2 has a higher afﬁnity for its substrates, when compared
to PAT1, but transports a narrower range of compounds [9,26,27].Fig. 1. Structures of amino acids and derivatives (see PubDespite the substrate speciﬁcity of this transport system being
characterised in some detail, the physiological role(s) of the
transporter is uncertain as, before isolation of the cDNAs, an
endogenous transport system with obvious PAT2-like characteristics
had not previously been identiﬁed in any tissue. However, a few clues
to the likely physiological functions of PAT2 in neuronal and renal
tissues have emerged over recent years. Immunolocalisation of PAT2
to the endoplasmic reticulum, recycling endosomes and plasma-
membrane of neurones in mouse brain [28] suggests that PAT2 may
be involved in amino acid movement in neuronal tissues. A Na+-
independent, relatively low afﬁnity, transporter of glycine, alanine
and proline had previously been identiﬁed in rat CNS tissues that
demonstrates some similarity in function to PAT2 [29,30]. In addition,
PAT2 protein (named Tramdorin 1 in the study)was immunolocalised
to myelinating Schwann cells suggesting a role in amino acid supply
during differentiation [31]. However, the strongest evidence for aChem website at http://pubchem.ncbi.nlm.nih.gov).
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colleagues [32,33]. The SLC36A2 (PAT2) gene was identiﬁed as the
major gene responsible for iminoglycinuria, a renal defect character-
ised by reduced reabsorption of glycine, proline and hydroxyproline
(Online Mendelian Inheritance in Man, OMIM: 242600). In ﬁve
pedigrees a single amino acid substitution (G87V) in PAT2 was
identiﬁed [32]. Expression of the G87V PAT2 mutant in Xenopus
oocytes produced a transporter with reduced activity compared to
wild-type PAT2 because of decreased afﬁnity for proline and glycine
[32]. In a separate pedigree, a splice donor site mutation in the ﬁrst
intron of SLC36A2was identiﬁed. This mutation produced a truncated
protein with no function [32]. Thus, a physiological role of PAT2 in the
renal proximal tubule is in the reabsorption of glycine, proline and
hydroxyproline. This role is emphasised by the recent ﬁnding that
reduced PAT2 expression in the apical membrane of mouse proximal
tubule is responsible in part for the developmental iminoglycinuria
observed in neonatal animals [33].
Although major advances have been made over recent years in our
understanding ofmembrane transporter function inmammalian tissues
it is also likely that many unidentiﬁed transport systems will play
unique physiological roles. These roles can be difﬁcult to deﬁne because
the function of an individual transporter may be masked, for example,
due to coexpression with other transport systems, low level of
expression, or limited expression in a sub-population of cells within a
mixed tissue. In the case of amino acid transporters, a major difﬁculty in
attributing transport of any individual compound toany single transportFig. 2. Interaction of proline derivatives with the amino acid transporter PAT2. A. L-[3H]Prolin
(control) and presence of unlabelled proline (Pro) or related derivatives (all 10 mM), L-thia
hydroxy-D-proline (CHDP), trans-3-hydroxy-L-proline (T3HP) and cis-4-hydroxy-L-proline (C
water-injected oocytes under identical experimental conditions). Data are mean±SEM (n=2
PAT2-mediated L-[3H]proline uptake (as in A above) by trans-4-hydroxy-L-proline (T4HP, ﬁl
hydroxy-L-proline (CHLP, ﬁlled triangles, n=19) (all 0.01–20 mM). Results are expressed as a
injected oocytes). Data aremean±SEM. C. Representative current traces from PAT2-expressing
measuredbyTEVC. D.Meandata for part C showing PAT2-mediated current (following subtracti
Data are mean±SEM (n=4–5). ***, pb0.001; *, pb0.05; ns, pN0.05, versus current change insystem is due to the overlapping substrate speciﬁcities and afﬁnities
observed between many transporters. The development of a panel of
selective substrates or, preferably, non-transported inhibitorswill allow
discriminationbetweenmovements throughdistinct transport systems.
Thus, the objective of this investigationwas to identify non-transported
inhibitors of the H+-coupled amino acid transporter PAT2. A previous
study [27] emphasised the potential of heterocyclic compounds as lead
candidates for this investigationof PAT2and twokey studies usingother
amino acid transporters [34,35] identiﬁed tryptophan analogues as the
most likely candidates. To allow identiﬁcation of transported substrates
and non-transported inhibitors, PAT2 was expressed in Xenopus laevis
oocytes and transport function characterised using a combination of
experimental approaches including radiotracer uptake and competition
(cis-inhibition) studies, radiotracer efﬂux and trans-stimulation, and
measurement of substrate-induced positive inward current using the
two-electrode voltage-clamp (TEVC) technique.
2. Materials and methods
2.1. Materials
All amino acids, analogues and derivatives were purchased from
Sigma-Aldrich (Poole, UK) except: guvacine and isoguvacine (Tocris,
Bristol, UK);α-methyl-D,L-tryptophan, D- and L-pipecolic acids (Bachem,
St. Helens, UK); and serotonin (Enzo Life Sciences, Exeter, UK).
Radiolabelled amino acids used were: β-[3-3H]alanine (speciﬁc activitye (100 μM) uptake (pH 5.5, Na+-free, 40 min) in PAT2-expressing oocytes in the absence
proline (TCA), trans-4-hydroxy-L-proline (T4HP), 3,4-dehydro-D,L-proline (DHP), cis-4-
HLP). Results are expressed as PAT2-speciﬁc uptake (following subtraction of uptake in
8–30). ***, pb0.001; *, pb0.05, versus control. B. Concentration-dependent inhibition of
led squares, n=20), trans-3-hydroxy-L-proline (T3HP, open squares, n=7), and cis-4-
percentage of the uptake in the absence of inhibitor (after subtraction of uptake in water-
andwater-injected oocytes upon exposure to proline and related derivatives (all 10 mM)
onof current induced inwater-injectedoocytes) evokedbyproline and relatedderivatives.
water-injected oocytes.
Fig. 3. Aminocyclohexanecarboxylic acids (ACHCs) do not interact with PAT2. A. L-[3H]
Proline (100 μM) uptake (pH 5.5, Na+-free) was measured in the absence (control) and
presence of proline (Pro) and various ACHCs (all 10 mM), 1-aminocyclohexanecar-
boxylic acid (1-ACHC), trans-2-aminocyclohexanecarboxylic acid (T2-ACHC), cis-4-
aminocyclohexanecarboxylic acid (C4-ACHC) and cis-2-aminocyclohexanecarboxylic
acid (C2-ACHC). Data are mean±SEM (n=18–20). ***, pb0.001; ns, pN0.05, versus
control. B. Representative current traces observed using PAT2 cRNA- or water-injected
oocytes during exposure to proline (Pro) and various aminocyclohexanecarboxylic
acids (all 10 mM). C. Mean data for part B showing PAT2-speciﬁc current change. Data
are mean±SEM (n=4). ***, pb0.001; ns, pN0.05, versus current change in water-
injected oocytes.
Fig. 4. Interaction of guvacine and isoguvacinewith PAT2. A. L-[3H]Proline (10 μM)uptake
(pH 5.5, Na+-free) was measured in the absence (control) and presence of proline (Pro),
isoguvacine (Isoguv) and guvacine (Guv) (all 10 mM). Data aremean±SEM (n=20). ***,
pb0.001, versus control. B. Representative current trace observed using PAT2-expressing
and water-injected oocytes during exposure to proline (Pro), isoguvacine (Isoguv) and
guvacine (Guv) (all 10 mM). C.Mean data for part B showing PAT2-speciﬁc currents. Data
are mean±SEM (n=4). ***, pb0.001; **, pb0.01, versus water-injected oocytes.
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(American Radiolabeled Chemicals, St. Louis, USA); [2-3H]glycine
(21 Ci mmol−1) (GE Healthcare, Little Chalfont, UK); and L-[2,3,4,
5-3H]proline (75–85 Ci mmol−1) (PerkinElmer, Beaconsﬁeld, UK).
2.2. Functional expression in Xenopus laevis oocytes
Female Xenopus laevis frogs were killed following Schedule 1
methods prior to surgical removal of the ovaries. Oocytes were
prepared as described previously [1,27]. Individual stage V/VI oocytes
were injected with 50 nl water (control) or cRNA (1 μg μl−1)synthesised by in vitro transcription of pCRII containing mouse
PAT1 [9] or pSPORT1 containing rat PAT2 [1] (there is 85% identity in
amino acid sequence between human and mouse PAT1, and 81%
identity between human and rat PAT2). Oocytes were maintained in
modiﬁed Barth's solution (18 °C, 2–7 days) until use.
2.3. Radiolabel ﬂux experiments
Oocytes were washed with Na+-free solution (in mM: 100
cholineCl; 2 KCl; 1 CaCl2; 1 MgCl2; 10 MES or 10 HEPES, adjusted to
required pH with Tris base). Radiolabel uptake experiments were
initiated by replacement of wash solution with 200 μl Na+-free
solution (pH 5.5 unless stated otherwise) supplemented with [3H]
amino acid (0.01–10 mM, 5 μCi ml−1). For cis-inhibition experiments,
uptake of [3H]amino acid was measured in the absence (control) and
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otherwise, amino acids and derivatives are used routinely in their L-
forms. Uptakes were measured over 40 min at 22 °C after which
time the oocytes were washed three times with ice-cold Na+-free
solution and lysed in 10% SDS before addition of scintillation
cocktail (PerkinElmer). For trans-stimulation experiments, oocytes
were pre-loaded with proline by microinjection of 50 nl L-[3H]
proline (25 mM, 0.1 μCi μl−1). Assuming an effective oocyte volume
of 250 nl [36], this equates to an intracellular proline concentration
of approximately 4 mM. Microinjected oocytes were allowed to
recover (15 min) in 200 μl modiﬁed Barth's solution (18 °C).
Individual oocytes were washed in Na+-free solution (pH 5.5) and
incubated (22 °C, 10 min) in 100 μl Na+-free solution (pH 5.5) in
the presence or absence of various compounds (all 10 mM). After
the 10 min efﬂux period, the incubation solution was removed for
scintillation counting and oocytes washed three times with ice-cold
Na+-free solution. Oocytes were lysed in 10% SDS before addition of
scintillation cocktail. Sample radioactivity was determined using an
LS6500 liquid scintillation counter (Beckman Coulter, High
Wycombe, UK).2.4. Electrophysiology
Two-electrode voltage-clamp (TEVC) experiments were per-
formed as described previously [25,27]. Water or cRNA-injected
oocytes were continuously superfused with Na+-free solution
(composition as per radiolabel ﬂux experiments) whilst clamped at
a membrane potential of −60 mV. Current changes evoked by
exposure (60–120 s) to experimental compounds (0.2–30 mM)
were recorded using pClamp software connected to a Geneclamp
500 ampliﬁer and Digidata 1200 (Axon Instruments, Molecular
Devices, Sunnyvale, USA) and analysed using Clampﬁt 8.2 (Axon
Instruments). Compound-induced current changes were calculated
by subtraction of baseline (average current recorded over 15 s before
addition of compound) from the average current recorded over the
ﬁnal 15 s of the exposure. Results are presented as cRNA-speciﬁc
current (calculated by subtraction of current evoked in water-injected
oocytes under identical experimental conditions) and representative
trace recordings.2.5. Data analyses
Data are mean±SEM (n=number of oocytes), except where
indicated in the text. Unless stated otherwise, results are expressed as
the cRNA-speciﬁc response (following subtraction of response in
water-injected oocytes under identical experimental conditions).
Statistical signiﬁcance was determined by unpaired or paired, two-
tailed Student's t-test or one-way analysis of variance (ANOVA) with
Tukey–Kramer multiple comparisons post-testing as appropriate.
pb0.05 was deemed statistically signiﬁcant. Kinetic parameters were
determined by ﬁtting data to Michaelis–Menten kinetics. Statistical
and kinetic analyses were performed using GraphPad Prism v.4
(GraphPad Software, San Diego, USA).Fig. 5. Interaction of piperidine carboxylates with PAT2. Representative current traces usin
10 mM) and/or: A. L-pipecolic acid (L-Pip); B. D-pipecolic acid (D-Pip), nipecotic acid (Nip), iso
B. Data represent the relative change in current observed when glycine (+Gly), isonipecot
(+L-Pip) (all 10 mM) are added to the superfusate in the continued presence of 0.3 mM glyc
by 0.3 mM glycine. Data for glycine (n=10) and L-pipecolic acid (n=5) are mean±SEM,
pb0.01; *, pb0.05; ns, pN0.05, versus the current observed in the presence of 0.3 mM glyc
expressing or water-injected oocytes during exposure to a saturating concentration (3 mM)
data for part D showing PAT2-speciﬁc current. Data are mean±SEM (n=4). **, pb0.01; *, pb
(ﬁlled squares) and L-[3H]pipecolic acid (open squares) (both 0.01–10 mM) uptake (pH 5.5
(following subtraction of uptake in water-injected oocytes). Data are mean±SEM (n=10)
(both 10 μM) uptake in PAT2-expressing oocytes at extracellular pH 5.5–8.0 (Na+-free). Re3. Results and discussion
3.1. Five-membered ring heterocyclic proline derivatives
The substrate speciﬁcity of PAT2 has been characterised to some
degree [1,9,26,27]. The major structural features that permit access and
translocation of a compound by PAT2 include the presence of a free
carboxyl head group, a small apolar side-chain, an amino head group in
theαposition, limitedmethylation of the aminogroup, and the distance
between thecharged carboxyl andaminoheadgroups [1,9,26,27]. Of the
twenty proteinogenic amino acids, glycine, L-alanine and L-proline are
transported substrates for PAT2 with the ﬁve-membered ring hetero-
cyclic L-proline (Fig. 1) having the highest afﬁnity (Km 0.1–0.2 mM)
[1,9,27]. Generally, PAT2 has a preference for L-enantiomers of amino
acids although this preference is weaker than that observed in most
other mammalian amino acid carriers [9,26,27]. It is possible that the
ring structure of proline might allow the substrate to be recognised in a
different orientation within the PAT2 binding site or even in distinct
orientations (as both an α- and a δ-imino acid) which might help
explain why both D-proline and trans-4-hydroxy-L-proline have similar
afﬁnities for PAT2 to that observed with L-proline [26,27,37,38].
However, despite this high afﬁnity for prolines, the maximum rate of
L-proline transport via PAT2 is less than that observed with glycine
[9,26,27]. This suggests that the heterocyclic structures (Fig. 1) are
translocated less efﬁciently than glycine, perhaps due to some sterical
hindrance within the transport pocket [26,27].
The lower turnover rate of PAT2 observed at high (mM)
concentrations of heterocyclic prolines [9,26,27] suggests that hetero-
cyclic amino acids are potential lead candidates in the identiﬁcation of
PAT2 inhibitors. L-[3H]Proline uptake (over 40 min) under optimal
transport conditions (pH 5.5, Na+-free solution) via PAT2 was
increased 17-fold above that in water-injected oocytes. PAT2-
mediated L-[3H]proline uptake was reduced by the proline derivatives
(all 10 mM) L-thiaproline (L-thiazolidine-4-carboxylic acid, TCA),
trans-4-hydroxy-L-proline (T4HP), 3,4-dehydro-D,L-proline (DHP),
cis-4-hydroxy-D-proline (CHDP), trans-3-hydroxy-L-proline (T3HP)
and cis-4-hydroxy-L-proline (CHLP) (Fig. 2A). Modiﬁcation within the
ring structure (replacement of a carbon atom by sulphur in L-
thiaproline; inclusion of the double-bond between the β- and γ-
carbon atoms in 3,4-dehydro-D,L-proline; or oxidation of the γ-carbon
in trans-4-hydroxy-L-proline) was well tolerated although the
position and orientation of the hydroxyl group (Fig. 1) in the
pyrrolidine ring (as observed in trans-4-hydroxy-L-proline, cis-4-
hydroxy-D-proline, trans-3-hydroxy-L-proline and cis-4-hydroxy-L-
proline) affected the relative afﬁnity of the compounds for PAT2
(Fig. 2A–B). Trans-4-hydroxy-L-proline, trans-3-hydroxy-L-proline
and cis-4-hydroxy-L-proline inhibited PAT2-mediated L-[3H]proline
uptake with IC50 values of 0.7±0.2, 13.1±4.2 and N20 mM,
respectively. Competition experiments alone do not discriminate
between cis-inhibition by a transported substrate or a non-trans-
ported inhibitor. Tomeasure PAT2-mediated transport of these proline
derivatives, substrate-induced inward currents were measured by
TEVCwhere the net chargemovement across the plasma-membrane is
due to H+ inﬂux coupled to amino acid import [9]. The relative
inhibitory effect of eachproline derivativewasmatchedby its ability tog PAT2-expressing and water-injected oocytes during exposure to glycine (Gly, 0.3 or
nipecotic acid (Isonip) (all 10 mM). C. Mean PAT2-speciﬁc current observed in parts A–
ic acid (+Isonip), nipecotic acid (+Nip), D-pipecolic acid (+D-Pip) or L-pipecolic acid
ine (control). Results are expressed as the fold change in current relative to that caused
and for isonipecotic acid, nipecotic acid and D-pipecolic acid are mean±SD (n=3). **,
ine (paired, two-tailed Student's t-test). D. Representative current traces using PAT2-
of glycine (Gly) in the presence and absence of 10 mM L-pipecolic acid (L-Pip). E. Mean
0.05, versus the current observed in the presence of 3 mM glycine alone. F. [3H]Glycine
, Na+-free) in PAT2-expressing oocytes. Results are expressed as PAT2-speciﬁc uptake
. G. pH-Dependent [3H]glycine (ﬁlled squares) and L-[3H]pipecolic acid (open squares)
sults are expressed as PAT2-speciﬁc uptake. Data are mean±SEM (n=9–10).
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that the current induced by trans-4-hydroxy-L-proline (T4HP) was
demonstrated previously [27] to be equivalent to that generated by
proline and is not shown here). No amino acid was able to induceFig. 6. Interaction of tryptophan and related derivatives with PAT2. A. L-[3H]Proline (10 μM
presence of proline (Pro) or tryptophan and related derivatives (all 10 mM), 5-hydroxy-L-try
L-tryptophan (1-Me-L-Trp), indole-3-propionic acid (3-IPA), tryptamine (Trypt), 1-methyl
expressed as PAT2-speciﬁc uptake. Data aremean±SEM (n=19–20). ***, pb0.001; ns, pN0.
presence of 5-hydroxy-L-tryptophan (OH-Trp) or α-methyl-D,L-tryptophan (Me-Trp) (bot
inhibitor (control). Data are mean±SEM (n=19–20). C. Representative current traces in PA
proline (Pro, open bar) in the presence or absence of 20 mM OH-Trp (solid bar) and 20 mM
column), OH-Trp (ﬁlled column) or Me-Trp (hatched column) (both 20 mM), as shown in p
oocytes. E. Mean PAT2-mediated current (in part C) when oocytes are exposed to proline (0
ﬁlled column) or Me-Trp (Pro+Me-Trp, hatched column) (both 20 mM). Results are expr
proline alone). ***, pb0.001 versus control. Data are mean ± SEM (n=5–6). F. Concentra
current (0.2 mM). Data are mean±SEM (n=5).current in water-injected oocytes (Fig. 2C). The close correlation
between inhibitory potency and induction of current demonstrates
that this group of compounds is unlikely to yield a non-transported
inhibitor of PAT2.) uptake (pH 5.5, Na+-free) in PAT2-expressing oocytes in the absence (control) and
ptophan (OH-Trp),α-methyl-D,L-tryptophan (Me-Trp), L-tryptophan (L-Trp), 1-methyl-
-D-tryptophan (1-Me-D-Trp), D-tryptophan (D-Trp) and serotonin (5-HT). Results are
05, versus control. B. L-[3H]Proline (10 μM) uptake (pH 5.5, Na+-free) in the absence and
h 0.1–30 mM). Results are expressed as a percentage of the uptake in the absence of
T2-expressing or water-injected oocytes (pH 5.5, Na+-free) during exposure to 0.2 mM
Me-Trp (hatched bar). D. Mean PAT2-speciﬁc current evoked by proline (0.2 mM, open
art C. Data are mean±SEM (n=5–6). ***, pb0.001; ns, pN0.05, versus water-injected
.2 mM) in the absence (Pro, open column) or presence of either OH-Trp (Pro+OH-Trp,
essed as a percentage of the control (the current observed in the presence of 0.2 mM
tion-dependent inhibition by Me-Trp (1–30 mM) of PAT2-mediated proline-induced
Fig. 7. Inhibition of PAT1- and PAT2-mediated amino acid uptake by tryptophan
derivatives. A. [3H]β-Alanine (100 μM, for PAT1) and L-[3H]proline (10 μM, for PAT2)
uptake were measured (pH 5.5, Na+-free) in the absence (control, open columns) and
presenceof 5-hydroxy-L-tryptophan (OH-Trp,ﬁlled columns)orα-methyl-D,L-tryptophan
(Me-Trp, hatched columns) (both 10 mM). Data are mean±SEM (n=20). ***, pb0.001;
ns, pN0.05, versus control. B. PAT1 (open columns) and PAT2 (ﬁlled columns) mediated
amino acid uptake (conditions as in A) in the absence (control) and presence of β-alanine
(β-Ala), proline (Pro), 5-hydroxy-L-tryptophan (OH-Trp),α-methyl-D,L-tryptophan (Me-
Trp), L-tryptophan (L-Trp), 1-methyl-L-tryptophan (1-Me-L-Trp), indole-3-propionic acid
(3-IPA), tryptamine (Trypt), 1-methyl-D-tryptophan (1-Me-D-Trp), D-tryptophan (D-Trp)
and serotonin (5-HT) (all 10 mM). Data are mean±SEM (n=19–20). Results are
expressed as percent control (uptake in absence of inhibitor).
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Previous observations [27] suggest that the four-membered ring
heterocyclic compounds D-cycloserine and L-2-azetidine carboxylate
are excellent PAT2 substrates. Thus, to try and identify non-transported
inhibitors, we focussed on amino acid analogues containing bulkier ring
structures. The six-membered ring cis-3-aminocyclohexanecarboxylic
acid is used to selectively discriminate between GABA transport by the
four GAT transporters (GAT1–4; SLC6A1, SLC6A13, SLC6A11 and
SLC6A12, respectively). Cis-3-aminocyclohexanecarboxylic acid has a
higher afﬁnity for GAT1 whereas β-alanine has a preference for GAT3
and 4 [39]. We were unable to obtain cis-3-aminocyclohexanecar-
boxylic acid for this investigation but we examined a series of related
aminocyclohexanecarboxylic acid (ACHC) compounds to determine
what effect positioning the aminogroupoutside the cyclic ring structure
(Fig. 1) had on PAT2 (in the proline derivatives investigated in Fig. 2 the
amino nitrogen is present within the heterocyclic ring). The ACHCs
tested (1-aminocyclohexanecarboxylic acid, 1-ACHC; trans-2-amino-
cyclohexanecarboxylic acid, T2-ACHC; cis-4-aminocyclohexanecar-
boxylic acid, C4-ACHC; cis-2-aminocyclohexanecarboxylic acid, C2-
ACHC) had no signiﬁcant (pN0.05) effect on PAT2-mediated L-[3H]
proline uptake (Fig. 3A). In addition, all ACHCs investigated failed to
induce inward current in PAT2-expressing oocytes (Fig. 3B–C). The
reason for the lack of interaction of these compounds with PAT2 is not
known but it is possible that the extra-cyclic nature of the amino
nitrogen (Fig. 1) will allow the six-membered ring to be recognised as a
bulky side-chainwhich, like bulky side-chain containingα-amino acids,
is not tolerated by PAT2.
3.3. Six-membered heterocyclic GABA analogues
Other heterocyclic GABA-related compounds are used to selec-
tively inhibit GAT transporters (such as guvacine) or as agonists for
GABAA receptors (such as isoguvacine) [39–41]. In contrast to the
ACHCs (Fig. 3), the amino nitrogen in guvacine and isoguvacine is
contained within the heterocyclic ring (which also contains an
unsaturated double-bond) (Fig. 1). Guvacine (Guv) and isoguvacine
(Isoguv) (both 10 mM) signiﬁcantly (pb0.001) inhibited L-[3H]
proline uptake (Fig. 4A) and the level of inhibition was consistent
with the ability to induce inward current in PAT2-expressing oocytes
(Fig. 4B–C) suggesting that both compounds are low afﬁnity
transported substrates of PAT2.
The six-membered heterocyclic ring (saturated) piperidine car-
boxylates pipecolic acid, nipecotic acid (a GAT transport inhibitor with
a similar structure to guvacine) and isonipecotic acid (a GABAA
receptor agonist with a similar structure to isoguvacine) differ from
each other by the distance between the amino and carboxyl groups
(Fig. 1). Our previous investigation demonstrated that isonipecotic
acid, nipecotic acid, and D- and L-pipecolic acids all inhibited PAT2-
mediated L-[3H]proline uptake [27] with L-pipecolic acid being the
most potent inhibitor (IC50 1.2 mM). However, all four compounds
were relatively poor at inducing inward currents via PAT2 [27]. This
observation suggested that these heterocyclic compounds were only
weakly translocated substrates for PAT2 and that they could prove
useful lead compounds in the development of PAT2 inhibitors.
When glycine in the superfusate is increased from a sub-saturating
(0.3 mM) to a saturating (10 mM) concentration (Km for glycine 0.5–
0.7 mM) [1,9] the increase in glycine-induced current (pb0.01)
represents an increase from sub-maximal to maximal PAT2 transport
(Fig. 5A and C). In contrast, when the total amino acid concentration is
increased from the sub-saturating 0.3 mM concentration of glycine to
the saturating concentration of L-pipecolic acid (L-Pip) (10 mM L-
pipecolic acid plus 0.3 mM glycine) a decrease in the amino acid-
induced current is observed (Fig. 5A and C). The current induced by
10 mM L-pipecolic acid is signiﬁcantly smaller (pb0.001) than that
observed in the presence of 10 mM glycine (Fig. 5A). Similarobservations were made with D-pipecolic (D-Pip), nipecotic (Nip)
and isonipecotic (Isonip) acids (Fig. 5B–C). The apparent inhibitory
effect (presumably due to a reduced rate of translocation) of L-
pipecolic acid is conﬁrmed in Fig. 5D–E where the current induced by
10 mM L-pipecolic acid alone is signiﬁcantly less (pb0.01) than that
observed following exposure to 3 mM glycine. In addition, the current
induced by the combination of saturating concentrations of L-
pipecolic acid and glycine (10 and 3 mM, respectively) is signiﬁcantly
less (pb0.05) than that induced by 3 mM glycine alone (Fig. 5D–E). In
this particular group of compounds, the distance between polar head
groups appears important as the greatest restriction to movement
through the transporter occurs with L-pipecolic acid whereas
elongation of the distance between carboxyl and amino groups, as
observed in isonipecotic acid (Fig. 1), improves translocation (as
measured by the isonipecotic acid-evoked current) (Fig. 5B–C).
It is possible that, rather than a slow translocation, the low level of
current observed in the presence of L-pipecolic acid is due to a
dissociation of amino acid and proton transport via PAT2 such that L-
pipecolic acid is transported in a partially uncoupled mode. However,
that does not appear to be the case as PAT2-mediated L-[3H]pipecolic
acid uptake is much reduced (pb0.001) compared to [3H]glycine due
to a reduction in Vmax from 934±22 to 224±19 pmol oocyte−1
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L-pipecolic acid and glycine are comparable to the relative levels of
current induced by the two compounds demonstrating that there is
no uncoupling of PAT2 transport. Finally, the low level of L-[3H]
pipecolic acid uptake was not due to altered pH-dependence of the
transporter as the uptake of L-[3H]pipecolic acid and [3H]glycine had
an identical pattern over the pH range (5.5–8.0) investigated
(Fig. 5G). The weakly transported nature of L-pipecolic acid via PAT2
demonstrates that it will have limited utility as a tool to provide
unequivocal evidence for PAT2 function in native tissues. However, it
should be useful when used in conjunction with other substrates and
inhibitors and it is a good lead structure to aid the design of novel
PAT2 inhibitors. The handling of L-pipecolic acid also distinguishesbetween PAT1 and PAT2 [14,27]. In PAT1, the levels of L-pipecolic acid
translocation and competition are comparable, whereas in PAT2 it is a
more effective blocker than transported substrate.3.4. Tryptophan derivatives are non-transported inhibitors of PAT2
Recently, certain members of a separate group of heterocyclic
amino acids, including the aromatic amino acid tryptophan and its
derivatives (all of which contain an indole scaffold) (Fig. 1), have been
identiﬁed as non-transported inhibitors of the amino acid transpor-
ters PAT1 (SLC36A1) and ATB0,+ (SLC6A14), respectively [34,35]. This
group of compounds was investigated to determine their effects on
PAT2 function. L-[3H]Proline uptake was inhibited signiﬁcantly
(pb0.001) by 5-hydroxy-L-tryptophan (OH-Trp), α-methyl-D,L-tryp-
tophan (Me-Trp), L-tryptophan (L-Trp), 1-methyl-L-tryptophan (1-
Me-L-Trp) and indole-3-propionic acid (3-IPA) (all 10 mM) whereas
the D-enantiomers D-tryptophan (D-Trp) and 1-methyl-D-tryptophan
(1-Me-D-Trp) were without effect (pN0.05) (Fig. 6A). The presence of
the carboxyl group seems important in PAT2 binding as the
decarboxylated amines tryptamine (Trypt) and serotonin (5-hy-
droxytryptamine, 5-HT) (both 10 mM) were without effect (pN0.05)
on L-[3H]proline uptake (Fig. 6A) whereas they interact with PAT1
with reasonable afﬁnity [34]. Methylation of the α carbon atom (α-
methyl-D,L-tryptophan) or nitrogen within the indole ring structure
(1-methyl-L-tryptophan) (Fig. 1) was tolerated. The inhibition
observed with indole-3-propionic acid suggests that the amino
nitrogen on the α carbon atom is not a prerequisite for PAT2 binding.
The greatest level of inhibition of PAT2-mediated amino
acid uptake was observed with the tryptophan derivatives 5-
hydroxy-L-tryptophan and α-methyl-D,L-tryptophan and their inter-
action with PAT2 was investigated further. 5-Hydroxy-L-tryptophan
and α-methyl-D,L-tryptophan inhibited L-[3H]proline uptake in a
concentration-dependent manner with IC50 values of 1.6±0.4 and
3.5±1.5 mM, respectively (Fig. 6B). Neither 5-hydroxy-L-tryptophan
nor α-methyl-D,L-tryptophan (both 20 mM) alone were able to elicit
signiﬁcant (pN0.05 versus water-injected oocytes) current in PAT2-
expressing oocytes (Fig. 6C–D). However, both 5-hydroxy-L-trypto-
phan and α-methyl-D,L-tryptophan (both 20 mM) caused signiﬁcant
(pb0.001) reductions in current evoked by 0.2 mM L-proline (Fig. 6C
and E). α-Methyl-D,L-tryptophan inhibited the L-proline-induced
current with an IC50 of 2.7±0.1 mM (Fig. 6F).Fig. 8. Trans-stimulation of PAT2-mediated L-[3H]proline efﬂux from oocytes discrimi-
nates between PAT2 substrates and non-transported inhibitors. PAT2-expressing and
water-injected oocytes pre-loaded with L-[3H]proline (approximately 4 mM) were
incubated (10 min) in pH 5.5 Na+-free solution in the presence or absence of various
amino acids (all 10 mM). A. A typical trans-stimulation experiment to illustrate efﬂux of L-
[3H]proline from PAT2-expressing (ﬁlled columns) and water-injected (open columns)
oocytes in the absence (control) or presence of glycine (Gly), 5-hydroxy-L-tryptophan
(OH-Trp) or α-methyl-D,L-tryptophan (Me-Trp) (all 10 mM). Data are mean±SEM
(n=10). ***, pb0.001; ns, pN0.05, versus water-injected oocytes. B. L-[3H]Proline efﬂux
was measured in the absence (control) or presence of glycine (Gly), L-alanine (Ala),
sarcosine (Sar), glutamic acid (Glu), isoguvacine (Isoguv), isonipecotic acid (Isonip),
guvacine (Guv), L-pipecolic acid (L-Pip), 5-hydroxy-L-tryptophan (OH-Trp) andα-methyl-
D,L-tryptophan (Me-Trp) (all 10 mM). Results are expressed as the percentage of L-[3H]
proline efﬂux in the presence of 10 mM extracellular glycine. Data are mean±SEM
(n=5–10). ***, pb0.001; ns, pN0.05, versus efﬂux under control conditions (efﬂux from
water-injectedoocytesunder identical conditions). C. Relationshipbetween the abilities of
various amino acids and derivatives to cis-inhibit PAT2-mediated amino acid uptake and
trans-stimulate PAT2-mediated amino acid efﬂux. For cis-inhibition, L-[3H]proline
(10 μM) uptake (pH 5.5, Na+-free) was measured in PAT2-expressing oocytes in the
absence and presence of unlabelled amino acids (all 10 mM). Results were determined as
PAT2-speciﬁc uptake (following subtraction of uptake in water-injected oocytes under
identical experimental conditions) and are expressed as a percent of the inhibition
observed in the presence of 10 mM glycine. Data are mean±SEM (n=20). For trans-
stimulation, data are taken from panel B, and are expressed as the percent of the trans-
stimulation observed in the presence of 10 mM glycine. The relationship [excluding L-
pipecolic acid (L-Pip), 5-hydroxy-L-tryptophan (OH-Trp) and α-methyl-D,L-tryptophan
(Me-Trp)] was analysed by linear regression (r2=0.82).
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methyl-D,L-tryptophan on amino acid transport by PAT1 and PAT2
demonstrates that both tryptophan derivatives (10 mM) inhibit PAT2
with similar efﬁcacy whereas 5-hydroxy-L-tryptophan causes a
signiﬁcantly greater (pb0.001) inhibition of amino acid uptake via
PAT1 than α-methyl-D,L-tryptophan (Fig. 7A). Extension of this
comparison to include all of the tryptophan derivatives used in
Fig. 6 allows the demonstration of a clear difference in the inhibition
proﬁle observed against amino acid uptake via PAT1 and PAT2
(Fig. 7B).
The ability of 5-hydroxy-L-tryptophan and α-methyl-D,L-trypto-
phan to inhibit PAT2-mediated amino acid transport and current,
combined with the lack of inward current observed, suggests either
that they represent non-transported blockers of PAT2 function or that
they are PAT2 substrates transported in an electroneutral manner.
3.5. Discrimination between transported substrates and non-transported
blockers of PAT2
As suggested above, a potential limitation of measurement of
substrate-induced currents by the TEVC technique is that electroneutral
movement of compounds through the carrier cannot be detected. This
has been demonstrated previously where H+-coupled short-chain fatty
acid transport via both PAT1 and PAT2 occurs in an electroneutral
fashion [42]. To address this issue, we determined the ability of various
compounds to trans-stimulate L-[3H]proline efﬂux from oocytes pre-
loaded by microinjection. In the absence of external amino acids, there
was no signiﬁcant (pN0.05) difference in L-[3H]proline efﬂux from
PAT2-expressing (22±3 (n=50) pmol oocyte−1(10 min)−1) or
water-injected (21±2 (n=50) pmol oocyte−1(10 min)−1) oocytes
(Fig. 8A). However, when the prototypical PAT2 substrate glycine
(10 mM) was added to the extracellular compartment, a signiﬁcant
increase (pb0.001) in L-[3H]proline efﬂux was observed from PAT2
(272±10 (n=50) pmol oocyte−1(10 min)−1) but not water-injected
(19±2(n=50)pmol oocyte−1(10 min)−1) oocytes,which represents
a 14-fold increase in efﬂux. An example is shown in Fig. 8A where the
presence of extracellular glycine (10 mM) is shown to increase L-[3H]
proline efﬂux whereas 5-hydroxy-L-tryptophan and α-methyl-D,L-
tryptophan (both 10 mM)have no effect (pN0.05 versuswater-injected
oocytes). These data are consistent with the inhibitory effects of 5-
hydroxy-L-tryptophan and α-methyl-D,L-tryptophan on amino acid-
induced current via PAT2 (Section 3.4) being due to the two compounds
acting as non-transported blockers of PAT2. Fig. 8B demonstrates that
the ability of a compound in the extracellular compartment to stimulate
L-[3H]proline efﬂux via PAT2 appears related to its ability to undergo
PAT2-mediated translocation. Thus, thePAT2 substrates glycine (Gly), L-
alanine (Ala) and sarcosine (Sar) all trans-stimulate L-[3H]proline efﬂux
(Fig. 8B)whereas glutamic acid (Glu), which is excluded from PAT2, has
no effect (Fig. 8B). The weakly transported heterocyclic compounds
stimulate relatively low levels of efﬂux with isonipecotic acid (Isonip)
being more effective than L-pipecolic acid (L-Pip). A direct relationship
between the relative ability of compounds to cis-inhibit PAT2-mediated
amino acid uptake and to trans-stimulate PAT2-mediated amino acid
efﬂux can be observed in Fig. 8C. A deviation from the linear
relationship, as observed with both 5-hydroxy-L-tryptophan and α-
methyl-D,L-tryptophan, provides evidence for the inhibitory effects
being due to the compounds acting as transport blockers rather than
transported substrates.
4. Conclusions
A number of proline, GABA and tryptophan derivatives were
examined to determine if they function either as transported
substrates or non-transported inhibitors of the H+-coupled amino
acid transporter PAT2. In general, the proline analogues were
transported substrates with varying afﬁnity for the transporterwhereas the GABA analogues, in particular L-pipecolic acid, appear
to be translocated relatively slowly. In contrast, both 5-hydroxy-L-
tryptophan and α-methyl-D,L-tryptophan function as non-trans-
ported inhibitors of PAT2. Although the afﬁnity of both compounds
is relatively low, compared to the high afﬁnity (IC50 approximately
250 μM) observed for the effect of α-methyl-D,L-tryptophan on amino
acid transport via ATB0,+ [35], they are likely to prove highly useful
experimental tools in the further investigation of the physiological
roles of PAT2. Our knowledge of the physiological importance of PAT2
is limited although it seems likely to have roles in amino acid
transport in both renal and neuronal tissues [26–28,31,32]. In
addition, a recent study examining changes in gene expression in
horses during implantation and early pregnancy demonstrates that
the SLC36A2 gene is highly upregulated in uterine tissues, perhaps
reﬂecting the increased nutrient demands of the developing concep-
tus [43]. Understanding the substrate/inhibitor proﬁle of a particular
amino acid transporter has a number of potential uses in pathophys-
iological conditions as amino acid transporters can be utilised to
mediate uptake of substrates that will alter cellular function or as a
mechanism to deprive cells of essential nutrients [35]. Finally, the
availability of non-transported inhibitors has utility in crystallograph-
ic studies, where the transport inhibitor can be used to trap a
transporter protein in the open-to-out conformation, as observed
with the leucine transporter LeuT [44].
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